Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
07
11
2020
pubmed:
5
1
2021
medline:
27
7
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity. A face-to-face consensus meeting was held in Tokyo, Japan (8-10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children's Dermatology Life Quality Index (CDLQI) for children and the Infant's Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.
Sections du résumé
BACKGROUND
The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting.
OBJECTIVES
To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity.
METHODS
A face-to-face consensus meeting was held in Tokyo, Japan (8-10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules.
RESULTS
It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children's Dermatology Life Quality Index (CDLQI) for children and the Infant's Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum.
CONCLUSIONS
For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.
Identifiants
pubmed: 33393074
doi: 10.1111/bjd.19751
pmc: PMC8359383
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-146Subventions
Organisme : Japanese Dermatological Association
Organisme : British Skin Foundation
ID : 8016
Organisme : Uehara Memorial Foundation
Organisme : Kyoto Prefectural University of Medicine and Kyushu University
Organisme : Nakatomi Foundation
Organisme : Lydia O'Leary Memorial Pias Dermatological Foundation
Organisme : National Institute for Health Research
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Allergy. 2017 Jan;72(1):146-163
pubmed: 27322918
J Clin Epidemiol. 2014 Jul;67(7):745-53
pubmed: 24582946
Br J Dermatol. 2001 Jan;144(1):104-10
pubmed: 11167690
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1773-1778
pubmed: 32176387
Ann Allergy Asthma Immunol. 2018 Dec;121(6):729-734.e4
pubmed: 30092267
Arch Dermatol. 2007 Jun;143(6):768-72
pubmed: 17576944
Med Care. 2007 May;45(5 Suppl 1):S3-S11
pubmed: 17443116
J Health Serv Res Policy. 2012 Jan;17(1):1-2
pubmed: 22294719
Br J Dermatol. 2019 Oct;181(4):761-769
pubmed: 30729499
Arch Dermatol Res. 2009 Sep;301(8):561-71
pubmed: 19326133
Qual Life Res. 2018 May;27(5):1147-1157
pubmed: 29435801
J Invest Dermatol. 2015 Jan;135(1):24-30
pubmed: 25186228
Br J Dermatol. 2018 May;178(5):e332-e341
pubmed: 29672835
BMC Dermatol. 2019 Nov 6;19(1):15
pubmed: 31690295
Trials. 2012 Aug 06;13:132
pubmed: 22867278
Allergy. 2018 Feb;73(2):451-458
pubmed: 28905999
Br J Dermatol. 2017 Apr;176(4):979-984
pubmed: 27858989
Acta Derm Venereol. 2019 Feb 1;99(2):211-217
pubmed: 30307024
Arch Dermatol. 2004 Dec;140(12):1513-9
pubmed: 15611432
Br J Dermatol. 1995 Jun;132(6):942-9
pubmed: 7662573
Trials. 2016 Sep 13;17(1):449
pubmed: 27618914
Acta Derm Venereol. 2015 Mar;95(3):345-6
pubmed: 25228475
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1124-1132
pubmed: 30720903
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):458-463
pubmed: 32745352
Pediatr Allergy Immunol. 2020 Jan;31(1):66-77
pubmed: 31505076
J Am Acad Dermatol. 2016 Nov;75(5):1038-1044
pubmed: 27522613
Br J Dermatol. 2020 Sep;183(3):524-536
pubmed: 31794074
Br J Dermatol. 2016 Jul;175(1):69-79
pubmed: 27436240
BMJ Open. 2017 Nov 15;7(11):e017731
pubmed: 29146642
J Allergy Clin Immunol. 2014 Oct;134(4):800-7
pubmed: 25282560
Patient. 2016 Jun;9(3):261-9
pubmed: 26518202
J Invest Dermatol. 2017 Oct;137(10):2069-2077
pubmed: 28859861
Curr Med Res Opin. 2020 Mar;36(3):367-376
pubmed: 31778083
Allergy. 2020 May;75(5):1264-1266
pubmed: 31725914